Critical care support of patients with nicotine addiction

Over 500 million of the current world population will die from diseases caused by smoking cigarettes. The symptoms and signs of nicotine withdrawal are not well described in the critically ill. Since the various conditions of critical illness may lead to clinical manifestations mimicking nicotine withdrawal, describing its specific manifestations may not be easy. A few case reports suggest that nicotine replacement therapy may ameliorate nicotine withdrawal in the critically ill. However, retrospective studies have found that it may increase mortality. Despite the abundance of active smokers, there is a paucity of data describing nicotine withdrawal, and its prevention and treatment options in the critically ill. Future studies are warranted to address these issues.

In the previous issue of Critical Care, Lucidarme and colleagues [1] describe the impact of nicotine abstinence on the clinical course of critically ill patients receiving mechanical ventilation for at least 48 hours. Th eir study included 144 patients, 44 smokers and 100 non-smokers. Th e smokers were more likely to be younger and male, have a history of alcoholism, and be admitted for septic shock compared to non-smokers. Th e results of the study showed active smoking history to be an independent risk factor for agitation.
Lucidarme and colleagues address an important clinical issue intensivists face daily in our practice. Th ere are 1.2 billion smokers in the world, half of whom will die from diseases caused by smoking [2]. Tobacco products are highly addictive [3,4] and abstinence from their use in active smokers can lead to withdrawal symptoms [5,6]. Th ese symptoms are often non-life threatening and are not well described in the critically ill. Mayer and collabora tors [7] reported fi ve cases of agitated delirium in smokers hospitalized for brain injury. Th ey attributed the delirium to nicotine withdrawal because of its improvement following nicotine replacement therapy (NRT). Tran-Van and colleagues [8] reported a case with difficulty to wean from mechanical ventilation, and restlessness attributed to nicotine withdrawal. Th e patient's condition improved following NRT.
Because of several confounding factors, it is diffi cult to determine the exact incidence of nicotine withdrawal in critically ill smokers. Critical illness, mechanical ventilation, and sepsis can be associated with various levels of encephalopathy. Th e symptoms and signs of the encephalo pathy may mimic the manifestations of nicotine withdrawal. Moreover, smokers may also have other addic tions, including alcohol and illicit drugs. Th e manifesta tions of abstinence from such addictive substances may not be easily distinguishable from the manifestations of nicotine withdrawal. Although compromised by the small sample size, Lucidarme and colleagues [1] have done their best to minimize the impact of confounding factors by matching cases and controls.
Th ere is a scarcity of data addressing the presence and extent of clinically important nicotine withdrawal symptoms in critically ill active smokers. Th e study by Lucidarme and colleagues is one step towards this. Since the symptoms and signs of nicotine withdrawal lack specifi city in the critically ill, eff ective therapy aimed specifi cally at preventing and treating nicotine withdrawal, with no eff ect on other conditions with similar manifestations, may help to defi ne the clinical course of nicotine withdrawal in the critically ill. Th e major currently available treatment options for nicotine addiction include NRT, bupropion, and varenicline. Several studies performed mostly in the outpatient setting have shown that NRT is safe and eff ective in ameliorating symptoms of nicotine withdrawal [9]. Although data justifying the use of NRT in the critically ill are nonexistent, some ICUs have developed protocols off ering it to all active smokers [10]. We recognize that hospitalization provides an excellent opportunity to intervene on

Abstract
Over 500 million of the current world population will die from diseases caused by smoking cigarettes. The symptoms and signs of nicotine withdrawal are not well described in the critically ill. Since the various conditions of critical illness may lead to clinical manifestations mimicking nicotine withdrawal, describing its specifi c manifestations may not be easy. A few case reports suggest that nicotine replacement therapy may ameliorate nicotine withdrawal in the critically ill. However, retrospective studies have found that it may increase mortality. Despite the abundance of active smokers, there is a paucity of data describing nicotine withdrawal, and its prevention and treatment options in the critically ill. Future studies are warranted to address these issues. nicotine addiction; however, NRT may not be a harmless intervention. Although the study was compromised by several limitations, our groups have shown that NRT may be associated with increased mortality in the critically ill [10]. A similar association was reported in patients under going cardiac surgery [11]. We have recently completed a prospective, cohort study of active smokers admitted to a medical ICU [12]. Th e study did not show statistically signifi cant association between NRT and mortality. However, NRT did not reduce the development of delirium.
Since nicotine addiction is a global health problem, some healthcare providers treat critically ill active smokers with NRT. Th eoretically, this approach may be benefi cial to critically ill smokers whose clinical course may be complicated by nicotine withdrawal. However, the clinical impact of nicotine withdrawal in the critically ill has not been well described. Although there are case reports suggesting that prevention and treatment of nicotine withdrawal may be benefi cial [7,8], retrospective studies have shown nicotine replacement therapy may increase mortality in the critically ill [10,11]. Future studies are warranted to describe the incidence and clinical manifestations of nicotine withdrawal. Moreover, interventions aimed at the prevention and treatment of nicotine withdrawal in the critically ill should be subjected to clinical trials before applying them to patients.